Tagged as: Lucamzi

FDA Approves Xbrane’s LUCAMZI™, a Biosimilar to LUCENTIS®

On October 29, 2026, Xbrane Biopharma announced that the FDA approved LUCAMZI™ (ranibizumab-blrz), a biosimilar to LUCENTIS® (ranibizumab). Ranibizumab is an anti-vascular endothelial growth factor (VEGF) therapy used to treat retinal vascular disorders, including neovascular (wet) age-related macular degeneration. According to Xbrane, the approval was supported by comparative structural and…

Read More

Xbrane Enters into Conditional Financing Deal Related to Ranibizumab Biosimilar

As we have previously reported, on June 21, 2023, the FDA accepted Xbrane’s sBLA for LUCAMZI, a proposed ranibizumab biosimilar to Genentech’s LUCENTIS (ranibizumab). On October 16, 2025, Xbrane Biopharma AB announced that it has entered into a financing solution with Fenja Capital II A/S (Fenja) to proactively secure the…

Read More